person
as of 2026-07-01Jeffrey A. Lieberman, MD
Jeffrey A Lieberman, MDJeffrey Lieberman, MD
at a glance
Roles: Principal Investigator, Study Director, Author
KOL signal score 9
1 publications · 1 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Columbia University
Roles
Principal Investigator, Study Director, Author
KOL signal
9
Publications
1 (1 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
5
CATIE- Schizophrenia Trial
NCT00014001Phase 4Completed
TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
NCT01003379Phase 2Completed
Clinical Trial of AVL-3288 in Schizophrenia Patients
NCT02978599Phase 1Completed
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
NCT00816907Phase 4Completed
ITI-007 (Lumateperone Tosylate) for Schizophrenia
NCT03817528Phase 2Terminated
Publications & congress
1
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2020 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
STUDY_DIRECTOR
PRINCIPAL_INVESTIGATOR